Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: A pilot study

Journal of Gastroenterology

Volumn 42, Issue 1, 2007, Pages 49-55

  Tanaka, Naoki ^a,b   Horiuchi, Akira ^a   Yamaura, Takahiro ^c   Komatsu, Michiharu ^b   Tanaka, Eiji ^b   Kiyosawa, Kendo ^b  

^a Showa Inan General Hospital   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Iida Municipal Hospital   (Japan)

Author keywords

fetoprotein; Albumin; HCV related cirrhosis; Iron reduction therapy; Protein energy malnutrition

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; IRON; SERUM ALBUMIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; IRON RESTRICTION; LIVER CIRRHOSIS; MALE; PATIENT SELECTION; PHLEBOTOMY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT WITHDRAWAL;

AGED; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; ASPARTATE AMINOTRANSFERASES; DIET THERAPY; FEMALE; HEPATITIS C; HUMANS; IRON; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHLEBOTOMY; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 33847637587     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-006-1967-y     Document Type: Article

References (24)

1. K Kiyosawa T Sodeyama E Tanaka Y Gibo K Yoshizawa Y Nakano 1990 Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus Hepatology 12 671-5 2170265 1:STN:280:By6D3cjmvVQ%3D
2. K Tarao Y Rino S Ohkawa O Endo K Miyakawa S Tamai 2004 Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of Child stage A Intervirology 47 65-71 15192269 10.1159/000077828 1:CAS:528:DC%2BD2cXksl2gu78%3D
3. H Hayashi T Takikawa N Nishimura M Yano T Isomura N Sakamoto 1994 Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron Am J Gastroenterol 89 986-8 8017395 1:STN:280:ByuB1cfgtF0%3D
4. MA Sochaski WJ Bartfay SR Thorpe JW Baynes E Bartfay DC Lehotay 2002 Lipid peroxidation and protein modification in a mouse model of chronic iron overload Metabolism 51 645-51 11979400 10.1053/meta.2002.30530 1:CAS:528:DC%2BD38XjsFaktLk%3D
5. N Tanaka K Kiyosawa 2004 Phlebotomy: A promising treatment for chronic hepatitis C J Gastroenterol 39 601-3 15235885
6. M Yano H Hayashi K Yoshioka Y Kohgo H Saito Y Niitsu 2004 A significant reduction in serum aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: A multicenter, prospective, randomized, controlled trial in Japan J Gastroenterol 39 570-4 15235875 10.1007/ s00535-003-1344-z 1:CAS:528:DC%2BD2cXlt1ylsLk%3D
7. C Corengia S Galimberti G Bovo A Vergani C Arosio R Mariani 2005 Iron accumulation in chronic hepatitis C: Relation of hepatic iron distribution, HFE genotype, and disease course Am J Clin Pathol 124 846-53 16416733 10.1309/X4UH-5Q68-Q4J3-GDNV 1:CAS:528:DC%2BD2MXhtlCjtb3K
8. K Ikeda S Saitoh M Kobayashi Y Suzuki A Tsubota F Suzuki 2000 Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection: Practical discriminant function using common laboratory data Hepatol Res 18 252-66 11058829 10.1016/ S1386-6346(00)00074-7
9. P Halfon M Bourliere G Penaranda R Deydier C Renou D Botta-Fridlund 2005 Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus Comp Hepatol 4 616008833 10.1186/ 1476-5926-4-6
10. J Poniachik DE Bernstein KR Reddy LJ Jeffers ME Coelho-Little F Civantos 1996 The role of laparoscopy in the diagnosis of cirrhosis Gastrointest Endosc 43 568-71 8781934 10.1016/S0016-5107(96)70192-X 1:STN:280:BymA2srmsVE%3D
11. S Murashima M Tanaka M Haramaki S Yutani Y Nakashima K Harada 2006 A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP Dig Dis Sci 51 808-12 16615008 10.1007/s10620-006-3211-2 1:CAS:528:DC%2BD28XjsFSls7w%3D
12. K Hanazaki S Kajikawa N Koide W Adachi J Amano 2001 Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: Univariate and multivariate analysis Am J Gastroenterol 96 1243-50 11316177 10.1111/j.1572-0241.2001.03634.x 1:STN:280:DC%2BD3MzntVWlsw%3D%3D
13. A Sangiovanni E Colombo F Radaelli A Bortoli G Bovo MA Casiraghi 2001 Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients Am J Gastroenterol 96 1575-80 11374702 10.1111/ j.1572-0241.2001.03780.x 1:STN:280:DC%2BD3M3ptF2jtw%3D%3D
14. T Furutani K Hino M Okuda T Gondo S Nishina A Kitase 2006 Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein Gastroenterology 130 2087-98 16762631 10.1053/j.gastro.2006.02.060 1:CAS:528:DC%2BD28XntVWit78%3D
15. JL Farber ME Kyle JB Coleman 1990 Mechanisms of cell injury by activated oxygen species Lab Invest 62 670-9 2162996 1:CAS:528:DyaK3MXktVGqtr0%3D
16. SP Hussain K Raja PA Amstad M Sawyer LJ Trudel GN Wogan 2000 Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: Oxyradical overload diseases Proc Natl Acad Sci USA 97 12770-5 11050162 10.1073/pnas.220416097 1:CAS:528:DC%2BD3cXotFylsbg%3D
17. F Farinati R Cardin M Fiorentino A D'Errico W Grigioni A Cecchetto 2001 Imbalance between cytoproliferation and apoptosis in hepatitis C virus-related chronic liver disease J Viral Hepat 8 34-40 11155150 10.1046/j.1365-2893.2001.00267.x 1:STN:280:DC%2BD3M3ktlSlsw%3D%3D
18. MB Troadec B Courselaud L Detivaud C Haziza-Pigeon P Leroyer P Brissot 2006 Iron overload promotes Cyclin D1 expression and alters cell cycle in mouse hepatocytes J Hepatol 44 391-9 16229922 10.1016/ j.jhep.2005.07.033 1:CAS:528:DC%2BD28XksVSjtw%3D%3D
19. J Kato M Kobune T Nakamura G Kuroiwa K Takada R Takimoto 2001 Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet Cancer Res 61 8697-702 11751387 1:CAS:528:DC%2BD38Xht1Ogug%3D%3D
20. F Kimura H Hayashi M Yano K Yoshioka T Matsumura T Fukuda 2005 Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C Hepatogastroenterology 52 563-6 15816478 1:CAS:528:DC%2BD2MXjt1KltLY%3D
21. M Tajika M Kato H Mohri Y Miwa T Kato H Ohnishi 2002 Prognostic value of energy metabolism in patients with viral liver cirrhosis Nutrition 18 229-34 11882395 10.1016/S0899-9007(01)00754-7 1:CAS:528:DC%2BD38Xhs1ylsLg%3D
22. K Suzuki A Kato M Iwai 2004 Branched-chain amino acid treatment in patients with liver cirrhosis Hepatol Res 30S S25-9 10.1016/ j.hepres.2004.08.007
23. Y Shiratori Y Ito O Yokosuka F Imazeki R Nakata N Tanaka 2005 Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival Ann Intern Med 142 105-14 15657158 1:CAS:528:DC%2BD2MXktVequ74%3D
24. GA Ramm RG Ruddell 2005 Hepatotoxicity of iron overload: Mechanisms of iron-induced hepatic fibrogenesis Semin Liver Dis 25 433-49 16315137 10.1055/s-2005-923315 1:CAS:528:DC%2BD28Xos1w%3D